Last reviewed · How we verify
DB-1311
At a glance
| Generic name | DB-1311 |
|---|---|
| Sponsor | DualityBio Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer (PHASE1, PHASE2)
- DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors (PHASE2)
- A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer (PHASE3)
- A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DB-1311 CI brief — competitive landscape report
- DB-1311 updates RSS · CI watch RSS
- DualityBio Inc. portfolio CI